$110.60 Million in Sales Expected for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) This Quarter

Wall Street brokerages forecast that Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPHGet Rating) will announce sales of $110.60 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Amphastar Pharmaceuticals’ earnings, with estimates ranging from $106.50 million to $118.20 million. Amphastar Pharmaceuticals posted sales of $103.02 million in the same quarter last year, which suggests a positive year over year growth rate of 7.4%. The business is expected to report its next earnings results after the market closes on Monday, January 1st.

On average, analysts expect that Amphastar Pharmaceuticals will report full-year sales of $494.06 million for the current financial year, with estimates ranging from $472.84 million to $537.00 million. For the next financial year, analysts expect that the firm will post sales of $546.94 million, with estimates ranging from $522.20 million to $584.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals (NASDAQ:AMPHGet Rating) last issued its quarterly earnings results on Thursday, March 10th. The company reported $0.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.04. Amphastar Pharmaceuticals had a net margin of 14.19% and a return on equity of 15.16%. The business had revenue of $120.89 million for the quarter, compared to analyst estimates of $111.38 million. During the same quarter in the prior year, the business posted $0.16 EPS.

A number of research analysts have issued reports on AMPH shares. Wells Fargo & Company upped their price target on shares of Amphastar Pharmaceuticals from $23.00 to $32.00 and gave the company an “equal weight” rating in a research note on Tuesday, March 15th. Zacks Investment Research upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $39.00 price target on the stock in a research note on Friday. Northland Securities upped their price objective on shares of Amphastar Pharmaceuticals from $33.00 to $43.00 in a report on Monday, April 11th. StockNews.com began coverage on shares of Amphastar Pharmaceuticals in a report on Thursday, March 31st. They issued a “buy” rating on the stock. Finally, Piper Sandler upped their price objective on shares of Amphastar Pharmaceuticals from $28.00 to $35.00 and gave the company an “overweight” rating in a report on Friday, March 11th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $37.25.

Shares of Amphastar Pharmaceuticals stock opened at $31.76 on Tuesday. The company has a current ratio of 3.06, a quick ratio of 2.17 and a debt-to-equity ratio of 0.17. Amphastar Pharmaceuticals has a 12-month low of $17.56 and a 12-month high of $44.46. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of 25.61 and a beta of 0.66. The firm’s 50 day simple moving average is $35.74 and its two-hundred day simple moving average is $27.57.

In related news, Director Michael A. Zasloff sold 10,000 shares of the stock in a transaction on Wednesday, March 16th. The shares were sold at an average price of $33.71, for a total transaction of $337,100.00. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO William J. Peters sold 7,900 shares of the stock in a transaction on Tuesday, March 15th. The stock was sold at an average price of $34.46, for a total transaction of $272,234.00. The disclosure for this sale can be found here. Insiders sold a total of 19,195 shares of company stock worth $651,692 over the last ninety days. Insiders own 27.80% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of AMPH. First Quadrant L P CA purchased a new position in Amphastar Pharmaceuticals during the fourth quarter valued at $36,000. Allworth Financial LP purchased a new position in Amphastar Pharmaceuticals during the fourth quarter valued at $42,000. Lazard Asset Management LLC purchased a new position in Amphastar Pharmaceuticals during the fourth quarter valued at $42,000. Advisor Group Holdings Inc. lifted its holdings in Amphastar Pharmaceuticals by 314.2% during the fourth quarter. Advisor Group Holdings Inc. now owns 2,311 shares of the company’s stock valued at $54,000 after purchasing an additional 1,753 shares in the last quarter. Finally, Royal Bank of Canada lifted its holdings in Amphastar Pharmaceuticals by 253.4% during the second quarter. Royal Bank of Canada now owns 3,534 shares of the company’s stock valued at $71,000 after purchasing an additional 2,534 shares in the last quarter. 59.79% of the stock is currently owned by institutional investors and hedge funds.

About Amphastar Pharmaceuticals (Get Rating)

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API.

Read More

Get a free copy of the Zacks research report on Amphastar Pharmaceuticals (AMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.